SynBiotic SE

SBX

Equity

ISIN DE000A3E5A59 / Valor 111572853

Xetra (2025-11-21)

EUR 2.05-1.44%

SynBiotic SE
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

SynBiotic SE is a leading entity in the European cannabis industry, focusing on the entire value chain from cultivation, research and development, production, to sales and distribution of cannabis-related products. Originating in the wellness and food sector, the company has expanded its reach to include the medical and anticipated recreational cannabis markets. With operations that include CBD production and extraction facilities, SynBiotic SE has established itself as one of Germany's premier hemp processors. Since its inception in 2015 by CEO and Founder Lars Müller, with a mission to unlock the therapeutic potential of cannabinoids, the company has been at the forefront of developing innovative products aimed at enhancing quality of life. SynBiotic SE has successfully launched and marketed brands, including Hempamed, which ranks among Germany's top CBD brands. As Europe's largest publicly-listed cannabis company, SynBiotic SE is recognized for its pioneering role in the industry, supported by a management team with over a century of combined experience. The company's strategic expansion within its core business areas and its significant presence in the German market, where the sale of CBD-containing food and wellness products is widely permitted, positions SynBiotic SE for continued growth, especially in light of increasing legalization and acceptance of cannabis products across Europe.

Summarized from source with an LLMView SourceSector: Finance

Revised Guidance

Management has adjusted the FY25 outlook from previously higher expectations, revising sales guidance from €30m to €17m and EBITDA from a projected profit of €1.7m to a loss of €1.5m. This change reflects the impact of softer market dynamics and increased caution among customers due to the potential regulatory step back affecting online distribution channels.

Market & Segment Dynamics

The Medical Cannabis segment, which benefited from prior regulatory easing, now faces reduced demand as online pharmacies and telemedicine channels adjust to new, stricter regulatory proposals. Additionally, anticipated liberalization in the Industrial Hemp sector has not materialized, contributing further to the subdued near-term performance.

Growth Prospects & Innovations

Despite current challenges, SynBiotic SE remains focused on long-term growth. The company is set to benefit from ongoing product innovation, including the launch of a new cannabis pastille designed to offer improved dosing and patient convenience, expected to hit the market in early 2026. Management and analysts are optimistic about structural improvements and further upward revisions in sales and profitability in the coming years.

Summarized from source with an LLMView Source

Key figures

-62.5%1Y

-85.0%3Y

%5Y

Performance

61.0%1Y

83.3%3Y

77.1%5Y

Volatility